CLDN24: A Drug Target / Disease Biomarker (G100132463)

Target Name: CLDN24

NCBI ID: G100132463

CLDN24

CLDN24: A Drug Target / Disease Biomarker

CLDN24 is a potential drug target and biomarker that is derived from the cerebral ventricular fluid (CVF). It is a type of protein that is expressed in the ventricles of the brain and has been shown to play a role in the development and progression of various neurological disorders, including Alzheimer's disease.

CLDN24 is a transmembrane protein that is expressed in the ventricles of the brain, including the dendrites, which are the extensions of the neurons that receive signals from other neurons. It is made up of four distinct chains that are held together by disulfide bonds. The two longest chains are the N-terminal and C-terminal chains, which contain the majority of the protein's functional domains.

One of the most interesting features of CLDN24 is its ability to interact with other proteins that are expressed in the brain. For example, CLDN24 has been shown to interact with the protein PDGF-BB, which is a key signaling molecule that is involved in the development and progression of many neurological disorders, including cancer. This interaction between CLDN24 and PDGF-BB suggests that CLDN24 may be a useful target for drugs that are designed to inhibit the activity of PDGF-BB.

Another potential mechanism by which CLDN24 may be involved in the development of neurological disorders is its role in the regulation of the blood-brain barrier (BBB). The BBB is a specialized barrier that separates the brain from the blood and helps to protect it from the harmful effects of foreign substances that could enter the brain. However, some diseases, such as Alzheimer's disease, are thought to involve the breakdown of the BBB and the subsequent entry of harmful substances into the brain. CLDN24 has been shown to be involved in the regulation of the BBB, which suggests that it may be a useful target for drugs that are designed to improve the function of the BBB.

In addition to its potential role in the regulation of the BBB, CLDN24 is also thought to be involved in the development and progression of certain neurological disorders. For example, CLDN24 has been shown to be involved in the development of amyloid plaques, which are thought to be a hallmark of Alzheimer's disease. Additionally, CLDN24 has been shown to be involved in the regulation of the production of neurotransmitters, which are important molecules that are used by the brain to communicate with other neurons. The dysfunction of neurotransmitter regulation that is thought to be associated with certain neurological disorders, such as Alzheimer's disease, may be related to the dysfunction of CLDN24.

Given the potential involvement of CLDN24 in the development and progression of a wide range of neurological disorders, it is an attractive target for drug development. There is currently a growing body of research focused on the development of drugs that are designed to inhibit the activity of CLDN24, with the goal of treating a wide range of neurological disorders. The identification of small molecules that are able to inhibit the activity of CLDN24 may be an important step in the development of these drugs.

In conclusion, CLDN24 is a protein that is expressed in the ventricles of the brain and has been shown to play a role in the development and progression of various neurological disorders. Its ability to interact with other proteins in the brain and its role in the regulation of the blood-brain barrier and neurotransmitter regulation suggest that it may be a useful target for drugs that are designed to treat a wide range of neurological disorders. Further research is needed to identify small molecules that are able to inhibit the activity of CLDN24 and to develop drugs that can effectively treat the associated neurological disorders.

Protein Name: Claudin 24

Functions: Plays a major role in tight junction-specific obliteration of the intercellular space, through calcium-independent cell-adhesion activity

The "CLDN24 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CLDN24 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets